CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS

Annual Review of Pharmacology and Toxicology

Vol. 46:101-122 (Volume publication date 10 February 2006)
First published online as a Review in Advance on August 19, 2005
https://doi.org/10.1146/annurev.pharmtox.46.120604.141254

Abstract

▪ Abstract CB1 and CB2 cannabinoid receptors are the primary targets of endogenous cannabinoids (endocannabinoids). These G protein–coupled receptors play an important role in many processes, including metabolic regulation, craving, pain, anxiety, bone growth, and immune function. Cannabinoid receptors can be engaged directly by agonists or antagonists, or indirectly by manipulating endocannabinoid metabolism. In the past several years, it has become apparent from preclinical studies that therapies either directly or indirectly influencing cannabinoid receptors might be clinically useful. This review considers the components of the endocannabinoid system and discusses some of the most promising endocannabinoid-based therapies.

Keywords